PTC Therapeutics, Inc. Available-for-sale Securities, Gross Unrealized Loss
PTC Therapeutics, Inc. (PTCT) reported Available-for-sale Securities, Gross Unrealized Loss of $31.50 thousand for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2014-03-06
- PTC Therapeutics, Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2013-12-31 was -$49.14K.
- PTC Therapeutics, Inc. available-for-sale securities, gross unrealized loss for the quarter ending 2013-09-30 was $77.05K.
- PTC Therapeutics, Inc. available-for-sale securities, gross unrealized loss for fiscal 2013 was $31.50K.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 6 month | Available-for-sale Securities, Gross Unrealized Loss 9 month | Available-for-sale Securities, Gross Unrealized Loss 12 month |
|---|---|---|---|---|
| 2013-12-31 | -$49.14K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-06 | $27.91K derived: sum of 2 quarters · filed 2014-03-06 | $31.50K 10-K · filed 2014-03-06 | |
| 2013-09-30 | $77.05K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $80.64K 10-Q · filed 2013-11-14 | ||
| 2013-06-30 | $3.59K 10-Q · filed 2013-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |